留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

真实世界研究:弥合临床实践指南与临床决策之间的距离

施秀青 阎思宇 黄桥 李绪辉 王永博 马文昊 商洪才 靳英辉

施秀青, 阎思宇, 黄桥, 李绪辉, 王永博, 马文昊, 商洪才, 靳英辉. 真实世界研究:弥合临床实践指南与临床决策之间的距离[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0217
引用本文: 施秀青, 阎思宇, 黄桥, 李绪辉, 王永博, 马文昊, 商洪才, 靳英辉. 真实世界研究:弥合临床实践指南与临床决策之间的距离[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0217
SHI Xiuqing, YAN Siyu, HUANG Qiao, LI Xuhui, WANG Yongbo, MA Wenhao, SHANG Hongcai, JIN Yinghui. Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0217
Citation: SHI Xiuqing, YAN Siyu, HUANG Qiao, LI Xuhui, WANG Yongbo, MA Wenhao, SHANG Hongcai, JIN Yinghui. Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0217

真实世界研究:弥合临床实践指南与临床决策之间的距离

doi: 10.12290/xhyxzz.2022-0217
基金项目: 

国家自然科学基金(82174230)

详细信息
    通讯作者:

    商洪才,E-mail:shanghongcai@126.com

    靳英辉,E-mail:jinyinghuiebm@163.com

  • 中图分类号: R012

Real World Research: Helping Clinical Practice Guidelines Span the Distance Between Itself and Clinical Decision Making

Funds: 

National Natural Science Foundation of China (82174230)

  • 摘要: 临床实践指南是制订临床决策的重要依据,但仍有诸多因素导致医生无法遵循指南,其中一个重要因素为指南的外部有效性受限,最终使得指南无法为临床决策的制订提供足够依据,此为指南与临床决策之间的距离。真实世界研究可增强指南的外部有效性,为临床决策的制订提供依据,为指南提供本土化证据、成本效益及其他方面相关证据,同时可监测指南的实施,弥补传统指南的证据不足,有助于弥合指南与临床决策之间的距离。在指南制订过程中,可考虑纳入高质量的真实世界研究和真实世界证据,以促进指南优化,助力指南质量提升。
  • [1] Institute of Medicine. Clinical Practice Guidelines We Can Trust.[M]. Washington (DC):National Academies Press (US), 2011.
    [2] U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices-Guidance for Industry and Food and Drug Administration Staff[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-wor ld-evidence-support-regulatory-decision-making-medical-devices.
    [3] U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program[EB/OL]. https://www.fda.gov/media/124748/download.
    [4] 国家药品监督管理局.真实世界数据用于医疗器械临床评价技术指导原则(征求意见稿)[EB/OL].(注明发布日期)[注明引用日期].https://www.cmde.org.cn/CL0066/20139.html.
    [5] 国家药品监督管理局. http://www.nmpa.gov.cn/WS04/CL2138/373175.html.
    [6] SHERMAN R E, ANDERSON S A, DAL PAN G J, et al. Real-World Evidence-What Is It and What Can It Tell Us?[J]. The New England journal of medicine, 2016, 375:2293-2297.
    [7] NEW J P, BAKERLY N D, LEATHER D, et al. Obtaining real-world evidence:the Salford Lung Study[J]. Thorax, 2014, 69:1152-1154.
    [8] CONCATO J, CORRIGAN-CURAY J. Real-World Evidence-Where Are We Now?[J]. The New England journal of medicine, 2022, 386:1680-1682.
    [9] U.S. Food and Drug Administration. 21st Century Cure Act[EB/OL].(注明发布日期)[注明引用日期]. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-curesact.
    [10] U.S. Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry[EB/OL].https://www.fda.gov/media/124748/download.
    [11] 国家药品监督管理局.国家药监局药审中心关于发布《真实世界研究支持儿童药物研发与审评的技术指导原则(试行)》的通告(2020年第22号)[EB/OL].(注明发布日期)[注明引用日期].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html.
    [12] ALONSO-COELLO P, IRFAN A, SOL I, et al. The quality of clinical practice guidelines over the last two decades:a systematic review of guideline appraisal studies[J]. Quality&safety in health care, 2010, 19:e58.
    [13] BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. European urology, 2022, 81:75-94.
    [14] CHANG S S, BOORJIAN S A, CHOU R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer:AUA/SUO Guideline[J]. The Journal of urology, 2016, 196:1021-1029.
    [15] MORI K,MIURA N,BABJUK M,et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma:A systematic review[J]. Urologic oncology, 2020, 38:774-782.
    [16] CHAMIE K, SAIGAL C S, LAI J, et al. Compliance with guidelines for patients with bladder cancer:variation in the delivery of care[J]. Cancer, 2011, 117:5392-5401.
    [17] POSEN A, BENKEN S, KALUZNA S D, et al. Poor guideline adherence in a real-world evaluation of hypertensive emergency management[J]. The American journal of emergency medicine, 2022, 51:46-52.
    [18] CABANA M D, RAND C S, POWE N R, et al. Why don't physicians follow clinical practice guidelines?A framework for improvement[J]. Jama, 1999, 282:1458-1465.
    [19] JIN Y H, TAN L M, KHAN K S, et al. Determinants of successful guideline implementation:a national cross-sectional survey[J]. BMC medical informatics and decision making, 2021, 21:19.
    [20] WONG G W, MIRAVITLLES M, CHISHOLM A, et al. Respiratory guidelines——which real world?[J]. Annals of the American Thoracic Society, 2014, 11 Suppl 2:S85-91.
    [21] GUYATT G H, OXMAN A D, VIST G E, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ (Clinical research ed), 2008, 336:924-926.
    [22] HERLAND K, AKSELSEN J P, SKJ NSBERG O H, et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?[J]. Respiratory medicine, 2005, 99:11-19.
    [23] HOFFMAN S N, TENBROOK J A, WOLF M P, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty:one-to eight-year outcomes[J]. Journal of the American College of Cardiology, 2003, 41:1293-1304.
    [24] W. BRETT M T H, U. GULLER, H.-R. ZERKOWSKI. CABG vs. PCI in coronary artery disease:what is the evidence?[J]. Card Surg Today, 2006, 2:43-55.
    [25] GRAPOW M T, VON WATTENWYL R, GULLER U, et al. Randomized controlled trials do not reflect reality:real-world analyses are critical for treatment guidelines![J]. The Journal of thoracic and cardiovascular surgery, 2006, 132:5-7.
    [26] KENNEDY-MARTIN T, CURTIS S, FARIES D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results[J]. Trials, 2015, 16:495.
    [27] CHEW S Y, KOH M S, LOO C M, et al. Making Clinical Practice Guidelines Pragmatic:How Big Data and Real World Evidence Can Close the Gap[J]. Annals of the Academy of Medicine, Singapore, 2018, 47:523-527.
    [28] HAYWARD R S. Clinical practice guidelines on trial[J]. CMAJ:Canadian Medical Association journal=journal de l'Association medicale canadienne, 1997, 156:1725-1727.
    [29] 周奇,董冲亚,王业明,等.循证医学理念在指导临床研究与实践中的作用:基于对抗病毒药物治疗新型冠状病毒肺炎的思考[J].中国循证医学杂志, 2022, 22:373-379.
    [30] SCHNEEWEISS S, PATORNO E. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments[J]. Endocrine reviews, 2021, 42:658-690.
    [31] U.S. Food and Drug Administration. FDA expands approved use of metastatic breast cancer treatment to include male patients[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm?utm_campaign=040419_PR_FDA% 20expands% 20use% 20of% 20breast% 20cancer% 20treatment% 20to% 20include% 20male% 20patients&utm_medium=email&utm_source=Eloqua (2019).
    [32] KHAN O, WILLIAMS M J, AMEZCUA L, et al. Multiple sclerosis in US minority populations:Clinical practice insights[J]. Neurology Clinical practice, 2015, 5:132-142.
    [33] WILLIAMS M J, AMEZCUA L, OKAI A, et al. Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis:3-Year Results from ESTEEM[J]. Neurology and therapy, 2020, 9:483-493.
    [34] KLEEBERG U R, LINDE H, G NTHER G, et al. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia:Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature[J]. Anticancer research, 2016, 36:2827-2838.
    [35] BEASLEY R, HOLLIDAY M, REDDEL H K, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma[J]. The New England journal of medicine, 2019, 380:2020-2030.
    [36] ALBERTSON T E, MURIN S, SUTTER M E, et al. The Salford Lung Study:a pioneering comparative effectiveness approach to COPD and asthma in clinical trials[J]. Pragmat Obs Res, 2017, 8:175-181.
    [37] MAGNUSSEN H, DISSE B, RODRIGUEZ-ROISIN R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J]. The New England journal of medicine, 2014, 371:1285-1294.
    [38] CHEN Y, WANG C, SHANG H, et al. Clinical practice guidelines in China[J]. BMJ (Clinical research ed), 2018, 360:j5158.
    [39] KEARON C, AKL E A, COMEROTA A J, et al. Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141:e419S-e496S.
    [40] KONSTANTINIDES S V, TORBICKI A, AGNELLI G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. European heart journal, 2014, 35:3033-3069, 3069a-3069k.
    [41] WANG C, ZHAI Z, YANG Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism:a randomized, multicenter, controlled trial[J]. Chest, 2010, 137:254-262.
    [42] FRANKLIN J M, GLYNN R J, MARTIN D, et al. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making[J]. Clinical pharmacology and therapeutics, 2019, 105:867-877.
    [43] 彭晓霞,舒啸尘,谭婧,等.基于真实世界数据评价治疗结局的观察性研究设计技术规范[J].中国循证医学杂志, 2019, 19:779-786.
    [44] CORTESE S, PANEI P, ARCIERI R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD):Data from the Italian National ADHD Registry[J]. CNS drugs, 2015, 29:865-877.
    [45] 谭婧,刘兴会,孙鑫.基于真实世界数据的疾病管理研究[J].协和医学杂志, 2019, 10:284-288.
    [46] CAMM A J, LIP G Y, DE CATERINA R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. European heart journal, 2012, 33:2719-2747.
    [47] ANDRADE A A, LI J, RADFORD M J, et al. Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation[J]. Journal of general internal medicine, 2015, 30:777-782.
    [48] QUANSTRUM K H, HAYWARD R A. Lessons from the mammography wars[J]. The New England journal of medicine, 2010, 363:1076-1079.
    [49] SHAUGHNESSY A F, COSGROVE L, LEXCHIN J R. The Need to Systematically Evaluate Clinical Practice Guidelines[J]. Journal of the American Board of Family Medicine:JABFM, 2016, 29:644-648.
    [50] STEELS S, VAN DER ZANDE M, VAN STAA T P. The role of real-world data in the development of treatment guidelines:a case study on guideline developers'opinions about using observational data on antibiotic prescribing in primary care[J]. BMC health services research, 2019, 19:942.
    [51] National Institue for Health and Care Excellence. NICE strategy 2021 to 2026-Dynamic, Collaborative, Excellent[EB/OL].(注明发布日期)[注明引用日期].https://www.nice.org.uk/about/who-we-are/corporate-publications/the-nice-strategy-2021-to-2026.
    [52] COLLINS R, BOWMAN L, LANDRAY M, et al. The Magic of Randomization versus the Myth of Real-World Evidence[J]. The New England journal of medicine, 2020, 382:674-678.
    [53] LEVY R I. Currently available lipid-lowering agents[J]. Hospital practice (Office ed), 1988, 23 Suppl 1:14-21.
    [54] COLLINS R, REITH C, EMBERSON J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet (London, England), 2016, 388:2532-2561.
    [55] RIMM E B, STAMPFER M J, ASCHERIO A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. The New England journal of medicine, 1993, 328:1450-1456.
    [56] STAMPFER M J, HENNEKENS C H, MANSON J E, et al. Vitamin E consumption and the risk of coronary disease in women[J]. The New England journal of medicine, 1993, 328:1444-1449.
    [57] Heart Outcomes Prevention Evaluation Study Investigators, YUSUF S, DAGENAIS G, et al. Vitamin E supplementation and cardiovascular events in high-risk patients[J]. The New England journal of medicine, 2000, 342:154-160.
    [58] 刘晓清,孙晓川.真实世界证据[J].协和医学杂志, 2017, 8:305-310.
    [59] TUNIS S R, STRYER D B, CLANCY C M. Practical clinical trials:increasing the value of clinical research for decision making in clinical and health policy[J]. Jama, 2003, 290:1624-1632.
    [60] 谭婧,程亮亮,王雯,等.患者登记研究的策划与患者登记数据库构建:基于观察性设计的真实世界研究[J].中国循证医学杂志, 2017, 17:1365-1372.
    [61] 唐立,康德英,喻佳洁,等.实效性随机对照试验:真实世界研究的重要设计[J].中国循证医学杂志, 2017, 17:999-1004.
    [62] 孙鑫,谭婧,唐立,等.基于真实世界证据的上市后药品评价技术框架体系:思考与建议[J].中国循证医学杂志, 2018, 18:277-283.
    [63] BOOTH C M, KARIM S, MACKILLOP W J. Real-world data:towards achieving the achievable in cancer care[J]. Nat Rev Clin Oncol, 2019, 16:312-325.
    [64] 徐浩,史大卓,刘保延,等.以临床实践数据为导向构建中西医结合临床指南的设想[J].中国中西医结合杂志, 2009, 29:544-547.
    [65] 王雯,刘艳梅,谭婧,等.回顾性数据库研究的概念、策划与研究数据库构建[J].中国循证医学杂志, 2018, 18:230-237.
  • 加载中
计量
  • 文章访问数:  89
  • HTML全文浏览量:  7
  • PDF下载量:  7
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-20
  • 修回日期:  2022-06-13
  • 网络出版日期:  2022-10-12

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!